Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis
<p>Subcutaneous body weight-adjusted low molecular weight heparin (LMWH) has been proven as effective and safe as intravenous aPTT-adjusted unfractionated heparin (UFH) for the treatment of patients with acute deep venous thrombosis (DVT). In this study we evaluate the efficacy of the initial...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2003
|
| In: |
Thrombosis and haemostasis
Year: 2003, Volume: 90, Issue: 08, Pages: 252-259 |
| ISSN: | 2567-689X |
| DOI: | 10.1160/TH02-09-0061 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1160/TH02-09-0061 Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1160/TH02-09-0061 
|
| Author Notes: | Hanno Riess, Klaus Koppenhagen, Alexander Tolle, Bettina Kemkes-Matthes, Michael Gräve, Frantisek Patek, Michael Drexler, Hans-Joachim G. Siemens, Job Harenberg, Gottfried Weidinger, Joachim Brom, Sylvia Haas |
| Summary: | <p>Subcutaneous body weight-adjusted low molecular weight heparin (LMWH) has been proven as effective and safe as intravenous aPTT-adjusted unfractionated heparin (UFH) for the treatment of patients with acute deep venous thrombosis (DVT). In this study we evaluate the efficacy of the initial treatment of proximal DVT with a fixed-dose, body weight-independent application of the LMWH Certoparin with a six month follow-up.</p> <p>In a prospective, multicentre, randomized, active-controlled study 1220 patients with objectively diagnosed proximal DVT were randomly assigned to subcutaneous 8000 U anti-factor Xa of Certoparin twice daily for 10 to 14 days or intravenous aPTT-adjusted UFH for 5 to 8 days. Both regimen were followed by oral anticoagulation for 6 months. The primary end point was the rate of symptomatic and objectively confirmed thromboembolic events within 6 months. The aim of the study was to demonstrate the non-inferiority of the Certoparin regimen as compared to UFH.</p> <p>The per-protocol analysis revealed 22 (3.8%) thromboembolic events in the Certoparin group and 24 (4.3%) in patients assigned to UFH within 6 months, thereby proving the non-inferiority (p<0.01), confirmed by intent-to-treat analysis (p<0.001). Major bleeding occurred in 6 and 7 patients started on Certoparin or UFH during the treatment period. Thromboembolic events were equally distributed in body weight categories with < 50,50-80 and >80 kg as followed:0,3.6% and 4.1% of patients for the Certoparin group and 0, 4.6% and 4.2% of patients for the UFH group. The same was true for major bleeding complications with 0, 2.9% and 1.5% for Certoparin and 0, 3.5% and 4.2% for UFH. Overall mortality was 1.9 % in the Certoparin group and 2.7 % in the UFH group.</p> <p>Fixed-dose body weight-independent subcutaneous LMWH Certoparin is at least as efficacious and safe as intravenous aPTT-adjusted UFH for the initial treatment of acute proximal DVT. This effect is maintained during a 6-months follow-up of treatment with oral anticoagulation.</p> |
|---|---|
| Item Description: | Elektronische Reproduktion der Druck-Ausgabe 06. Dezmber 2017 Gesehen am 21.04.2022 |
| Physical Description: | Online Resource |
| ISSN: | 2567-689X |
| DOI: | 10.1160/TH02-09-0061 |